Trial
NCT00206687
STEPS Trial - Spheramine Safety and Efficacy Study
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Bayer
Collaborators
Titan Pharmaceuticals
Condition
Parkinson Disease
Intervention
Spheramine (BAY86-5280)
Why stopped
Study was completed, only life long extended follow-up phase was discontinued after 12 years.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-10-31